NCT06052748View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-223

PHASE3CompletedINTERVENTIONAL
Enrollment

502

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

March 27, 2025

Study Completion Date

April 2, 2025

Conditions
Hypertension,Essential
Interventions
DRUG

AD-223A

PO, Once daily(QD), 8weeks

DRUG

AD-223B

PO, Once daily(QD), 8weeks

DRUG

AD-223C

PO, Once daily(QD), 8weeks

DRUG

AD-223A Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-223B Placebo

PO, Once daily(QD), 8weeks

DRUG

AD-223C Placebo

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

Hanyang University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT06052748 - A Study to Evaluate the Efficacy and Safety of AD-223 | Biotech Hunter | Biotech Hunter